Penn study details robust T-cell response to mRNA COVID-19 vaccines

The results underline the importance of a second dose and include implications for booster shots.

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system’s T cells—the heavy armor of the immune system—according to a study from researchers in Penn’s Perelman School of Medicine. Although recent studies of vaccines tend to focus on the antibody response, the T-cell response is also an important and potentially more durable source of protection—yet little has been reported so far on the T-cell response to COVID-19 vaccines.

In the new study, which appears in the journal Immunity, the Penn Medicine researchers analyzed the T-cell responses in 47 healthy people who received two doses of the Moderna and Pfizer/BioNTech mRNA vaccines.

The results reveal the complex details of how the T-cell response to these vaccines unfolds, and underline the importance of a second dose for people with no history of COVID-19. The findings showed, however, that in people with a history of COVID-19, the T-cell response was already robust after the first vaccine dose, with no significant increase after the second dose, which may have implications for potential future booster shots.

“Our findings underscore the fact that we need to look at T cells, not just antibodies, if we want a complete picture of the vaccine response for those who have not had COVID-19 and for those who have recovered from the disease,” says senior author E. John Wherry, chair of the Department of Systems Pharmacology and Translational Therapeutics and director of the Penn Institute for Immunology in the Perelman School of Medicine.

 

Comments are closed.